In a xenograft model [59], LY3164530 had more anti-tumor effect in comparison to emibetuzumab and cetuximab, and was effective against NSCLC resistant to EGFR inhibitors [60]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.